Health Care & Life Sciences » Pharmaceuticals | Catalyst Biosciences Inc.

Catalyst Biosciences Inc.

Catalyst Biosciences Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.35
Market Cap
$111.53 M
Shares Outstanding
11.98 M
Public Float
9.65 M

Profile

Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.catalystbiosciences.com
Updated 07/08/2019
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration.

Financials

View All

Nassim Usman
President, Chief Executive Officer & Director
Stephen Anthony Hill
Director